Abstract: Method for the aseptic filling of a bag with a pharmaceutical product or liquid which comprises the following steps: a) a first step in which the cap is inserted in the inlet of the bag; b) a second step in which said cap is raised and the pharmaceutical product or liquid concerned is introduced; c) a third step in which the cap is re-inserted in the inlet of the bag; and d) a fourth step in which the cap and the inlet of the bag are welded.
Type:
Application
Filed:
October 21, 2015
Publication date:
April 28, 2016
Applicant:
GRIFOLS, S.A.
Inventors:
Jordi BOIRA BONHORA, Miquel Faba Vilella, Daniel Fleta Coit
Abstract: The invention relates to methods and kits for the analysis of the sialylation of gluco-proteins. The samples of gluco-protein are incubated separately under three conditions: with beta-galactosidase, with beta-galactosidase+alpha-sialidase, and without an enzyme. After the enzyme treatment, high performance anion exchange chromatography with pulsed amperometric detection (HPAEC PAD) is used to make a quantitative determination of the total galactose in the sample, the non sialylated galactose and the exogenous galactose in the medium. The determination of said values makes it possible to deduce the percentage of sialylation of the gluco-protein.
Abstract: The present invention relates to the use of alpha-1-antitrypsin for the preparation of effective drugs for the treatment of chronic fatigue syndrome. In addition, the present invention relates to the use of plasma or other therapeutic forms with an alpha-1-antitrypsin content sufficient to obtain a dose of 6 mg or more of alpha-1-antitrypsin per kg of body weight at a frequency of between 1 and 31 days.
Abstract: A process for obtaining an IgG composition involves heat treatment. This process obtains an IgG composition from an IgG solution partly purified from human plasma, in which by applying intermediate heat treatment and without using reagents to precipitate high molecular weight aggregates/polymers and/or proteins virtually total elimination of the IgG polymers generated during the process is achieved. Furthermore this process offers high productivity, lower production costs and is easy to implement in comparison with the processes of the know art. In addition to this, by using this process stability is imparted to the final product in liquid.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
December 1, 2015
Assignee:
GRIFOLS, S.A.
Inventors:
Pere Ristol Debart, Salvador Grancha Gamon
Abstract: Devices, systems, and methods for delivery of therapeutics, in particular thrombolytic agents, in particular plasmin, are provided. The devices, systems, and methods also provide for occlusion of a vessel or graft distal and/or proximal to a treatment zone. Also provided are devices, systems, and methods that trap emboli.
Type:
Grant
Filed:
April 9, 2013
Date of Patent:
May 12, 2015
Assignee:
Grifols, S.A.
Inventors:
Dean Chamberlain, Valery Novokhatny, David Fineberg
Abstract: Device for taking samples of liquid from a collection container, characterized in that it comprises a support for liquid sample collection containers; a support for a set of containers into which the sample of liquid will be deposited; a support for connection elements; a container handling mechanism; and a device for inserting the containers into which the sample of liquid will be deposited into the connection element.
Type:
Grant
Filed:
January 19, 2010
Date of Patent:
April 28, 2015
Assignee:
Grifols, S.A.
Inventors:
Diego Lopez Alvarez, Sergi Roura Adell, Francisco Rodriguez Garcia, Oriol Causi Casamor, Shinji Wada
Abstract: A hermetically-sealed plastics container for blood derivative products is provided. The container may have an internal surface and an external surface, characterised in that it comprises an RFID inlay between the internal surface and the external surface.
Type:
Application
Filed:
January 31, 2013
Publication date:
January 8, 2015
Applicant:
GRIFOLS, S.A.
Inventors:
Carlos Roura Fernandez, Victor Grifols Roura, Jordi Boira Bonhora
Abstract: A culture medium for human mesenchymal stem cells (hMSC) includes a mesenchymal stem cell basal medium; human leucocyte/platelet coat lysate; insulin; sodium selenite; ethanolamine; and basic fibroblast growth factor. This culture medium is effective for growing hMSC lines, including those which do not grow in culture medium normally used for this type of cell.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
September 16, 2014
Assignee:
Grifols, S.A.
Inventors:
Jose Maria Diez Cervantes, Rodrigo Gajardo Rodriguez
Abstract: The present invention relates to a new suspension medium or diluent solution for red blood cells for use in haematological methods. The suspension medium or diluent solution for red blood cells may comprise a combination of two or more amino acids of any group, and preserves the red blood cells in the sample for at least 8 weeks.
Type:
Grant
Filed:
June 22, 2007
Date of Patent:
August 12, 2014
Assignee:
Grifols, S.A.
Inventors:
Daniel Martorell Pena, Ma del Carmen Traves Polo, Jordi Farre Leon, Josefina Castells Parera
Abstract: The invention relates to methods and kits for the analysis of the sialylation of gluco-proteins. The samples of gluco-protein are incubated separately under three conditions: with beta-galactosidase, with beta-galactosidase+alpha-sialidase, and without an enzyme. After the enzyme treatment, high performance anion exchange chromatography with pulsed amperometric detection (HPAEC PAD) is used to make a quantitative determination of the total galactose in the sample, the non sialylated galactose and the exogenous galactose in the medium. The determination of said values makes it possible to deduce the percentage of sialylation of the gluco-protein.
Abstract: A culture medium for human mesenchymal stem cells (hMSC) includes a mesenchymal stem cell basal medium; human leucocyte/platelet coat lysate; insulin; sodium selenite; ethanolamine; and basic fibroblast growth factor. This culture medium is effective for growing hMSC lines, including those which do not grow in culture medium normally used for this type of cell.
Type:
Application
Filed:
March 15, 2013
Publication date:
May 15, 2014
Applicant:
Grifols, S. A.
Inventors:
Jose Maria DIEZ CERVANTES, Rodrigo Gajardo Rodriguez
Abstract: A process for obtaining an IgG composition involves heat treatment. This process obtains an IgG composition from an IgG solution partly purified from human plasma, in which by applying intermediate heat treatment and without using reagents to precipitate high molecular weight aggregates/polymers and/or proteins virtually total elimination of the IgG polymers generated during the process is achieved. Furthermore this process offers high productivity, lower production costs and is easy to implement in comparison with the processes of the know art. In addition to this, by using this process stability is imparted to the final product in liquid.
Abstract: Device for emptying a bag containing a frozen blood-derived product, including: a cutting device; an extractor for the product, a hopper for receiving the product, a device for transporting the bag from a receiving area to the plasma extractor, this transporting device including a robotic arm with a gripper which, in turn, includes: two catching arms, each defining at least a distal end and a proximal end, and an actuator, in which the actuator controls a mechanism for modifying the distance separating the distal ends of the gripper arms to catch the bag by its lower surface.
Abstract: The apparatus comprises a single transportable structure provided with several separate compartments located in a vertical stack within a cabinet, with means for the vertical transport of gel cards, means for the transport of units for moving the cards and pipetting probes, being displaceable to the entire transverse cross-section of the compartments in at least two of the vertical compartments or floors through moving along coordinate axes X, Y, Z at right-angles, and control means so that automatic functioning can take place simultaneously with manual actions to load and unload the necessary materials (samples, reagents, cards, wash solutions and waste solutions) in a random manner.
Abstract: A method and device for treating cholesterol disorders includes administering at least one treatment regime including two or more rounds of plasmapheresis to a patient having abnormal total cholesterol, abnormal LDL levels and/or abnormal HDL levels prior to treatment. Treatment according to the method results in decreased LDL levels in patients having abnormal LDL levels and increased HDL levels in patients having abnormal HDL levels. Each subsequent round of plasmapheresis is conducted weekly, but no more than twice per week.
Type:
Application
Filed:
March 12, 2012
Publication date:
September 12, 2013
Applicant:
GRIFOLS, S.A.
Inventors:
Victor GRIFOLS LUCAS, Victor Grifols Roura